New Affordable HIV-Prevention Injection Advances: India’s Dr. Reddy’s Gets FDA Nod for Generic Drug

A major breakthrough in HIV prevention

In a significant development in the global fight against HIV/AIDS, India’s pharmaceutical company Dr. Reddy’s Laboratories has received tentative approval from the US Food and Drug Administration (FDA) for its generic version of lenacapavir, a long-acting HIV-prevention medicine.

Announced on November 2, 2026, the regulatory milestone brings affordable HIV prevention closer to millions of people, particularly in low- and middle-income countries.

Lenacapavir is administered as an injection twice a year, offering an alternative to traditional pre-exposure prophylaxis (PrEP), which generally requires taking medication regularly, often every day.

The development has attracted international attention because the generic version is expected to cost approximately $40 per person annually in 120 eligible low- and middle-income countries.

What is lenacapavir?

Lenacapavir is a long-acting antiviral medicine developed by Gilead Sciences. It works by targeting the HIV capsid, a protein structure that plays an important role in the virus’s life cycle.

When used for HIV prevention, it helps protect HIV-negative individuals from acquiring the infection.

Clinical trials have demonstrated exceptionally high effectiveness. In one major trial involving adolescent girls and young women, no new HIV infections occurred in the lenacapavir group during the study period. Another trial also demonstrated very high protection among other populations.

In June 2025, the US FDA approved Gilead’s original lenacapavir product, marketed as Yeztugo, for HIV prevention.

Why is the $40 price significant?

The cost of innovative medicines has historically been a major obstacle to healthcare access in developing countries.

The branded version of lenacapavir has a US list price of approximately $28,000 per year. In comparison, the proposed generic price of $40 annually could make the treatment substantially more affordable in eligible countries.

The affordability agreement involves Dr. Reddy’s Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and the Wits Reproductive Health and HIV Institute (Wits RHI).

Under the agreement, the generic product is intended for 120 low- and middle-income countries covered by Gilead’s voluntary licensing arrangements.

What does this mean for India?

India plays an important role in the global generic pharmaceutical industry. The development highlights the country’s growing contribution to affordable medicines and international public health.

Dr. Reddy’s achievement could strengthen India’s position in the development and manufacturing of complex generic medicines.

However, the tentative FDA approval does not automatically mean that the injection is immediately available in Indian hospitals or pharmacies. Further regulatory steps, including relevant national approvals and procurement arrangements, will be necessary.

Initial supplies are expected to reach some eligible countries before the end of 2026, with broader availability anticipated in 2027.

Important benefits of the new injection

The twice-yearly injection could offer several advantages:

• Less frequent dosing: Two injections annually instead of taking a daily PrEP pill.
• Improved convenience: May help people who find daily medication difficult to maintain.
• Potential affordability: The proposed $40 annual generic price could expand access.
• Greater prevention choices: Provides another option for people seeking HIV prevention.
• Public health impact: Wider access could help reduce new HIV infections.

Important precautions

Although lenacapavir offers promising protection against HIV, it is not a treatment for people who already have HIV.

Individuals must undergo HIV testing before starting the medicine and at recommended follow-up visits. Healthcare professionals should assess eligibility, administer the injections and monitor patients.

Possible side effects include injection-site reactions, headache and nausea.

It is also important to understand that lenacapavir does not prevent other sexually transmitted infections (STIs), such as syphilis, gonorrhoea or chlamydia. Condoms and appropriate sexual health screening remain important.

Challenges ahead

Despite the promising development, affordable manufacturing alone will not guarantee universal access.

Governments, healthcare providers and public health organisations will need to address several challenges, including:

• National regulatory approvals.
• Reliable manufacturing and distribution.
• Healthcare infrastructure and trained medical professionals.
• Public awareness and education.
• Affordable procurement and equitable distribution.

Ensuring that vulnerable communities can access the injection will be essential to achieving its full public health potential.

Conclusion: A promising step towards ending the HIV epidemic

The tentative FDA approval of Dr. Reddy’s generic lenacapavir represents an important milestone in making innovative HIV prevention more affordable.

A twice-yearly injection priced at approximately $40 annually could provide a valuable alternative to daily PrEP medication for millions of people in eligible countries.

However, the real success of this development will depend on how quickly governments and healthcare systems turn regulatory progress into practical access.

The message is clear: HIV prevention should not be a privilege determined by income. Affordable and accessible prevention could bring the world one step closer to ending the HIV epidemic.

---

Sources and references

1. Reuters – Dr. Reddy’s receives tentative US FDA approval for generic HIV prevention drug, November 2, 2026.
2. Clinton Health Access Initiative (CHAI) – First generic injectable lenacapavir receives FDA tentative approval, November 2, 2026.
3. Wits Reproductive Health and HIV Institute – Generic lenacapavir announcement, November 2, 2026.
4. US FDA – Regulatory information on HIV-prevention medicines.

Suggested SEO keywords: HIV prevention injection, affordable HIV medicine, lenacapavir, Dr. Reddy’s Laboratories, HIV prevention India, generic HIV drug, PrEP injection, HIV/AIDS news 2026.